Product Information
MATZIM LA 300 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $1.9283 per EA under NDC 52544069330. Its NADAC has been published 597 times since Nov 28, 2013.
FDA first approved this application on Mar 15, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
52544069330
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DILTIAZEM HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077686FDA Approved
3/15/2010
TE Code
AB
On Market Since
3/28/2011
Pharmacological Classes
Price Statistics
The NADAC for MATZIM LA 300 MG TABLET has been published 597 times since Nov 28, 2013, and over the history we have for it it has declined 41.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9283 per EA |
|---|---|
| All-time high | $3.3997 (Jun 15, 2016) |
| All-time low | $1.2965 (Jan 21, 2026) |
| 52-week high | $2.7685 |
| 52-week low | $1.2965 |
| Median price | $3.1678 |
| Average price | $2.9543 |
| Largest weekly change | +33.9% (Oct 23, 2024) |
| Weeks tracked | 597 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Diltiazem Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MATZIM LA 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MATZIM LA 300 MG TABLET, manufactured by Actavis Pharma, Inc., is $1.9283 per EA (NDC 52544069330), effective Sep 30, 2026.
How has the price of MATZIM LA 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for MATZIM LA 300 MG TABLET has declined 41.8%. It has been tracked across 597 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MATZIM LA 300 MG TABLET?
Since Nov 28, 2013, the NADAC for MATZIM LA 300 MG TABLET has ranged from a low of $1.2965 (Jan 21, 2026) to a high of $3.3997 (Jun 15, 2016), with a median of $3.1678 per EA.
Are there cheaper alternatives to MATZIM LA 300 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DILTIAZEM 24H ER(LA) 300 MG TB, is $1.7746 per EA — about 8% below MATZIM LA 300 MG TABLET.
Who manufactures MATZIM LA 300 MG TABLET?
MATZIM LA 300 MG TABLET (NDC 52544069330) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.